D013, D326, D337

DRUG6 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Dyslipidemia Patients With HypertensionHypertension and Dyslipidemia

Phase 1

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

CompletedNCT04694989

Chong Kun Dang PharmaceuticalHypertension and Dyslipidemia

Start: 2021-02-20End: 2021-05-04Updated: 2021-07-07

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

CompletedNCT04987970

Chong Kun Dang PharmaceuticalHypertension and Dyslipidemia

Start: 2021-09-12End: 2021-11-27Updated: 2022-02-03

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

CompletedNCT05245084

Chong Kun Dang PharmaceuticalHypertension and Dyslipidemia

Start: 2022-03-15End: 2022-06-20Updated: 2022-09-28

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

CompletedNCT05552495

Chong Kun Dang PharmaceuticalHypertension and Dyslipidemia

Start: 2022-09-23End: 2022-12-12Updated: 2023-01-12

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

CompletedNCT05698043

Chong Kun Dang PharmaceuticalHypertension and Dyslipidemia

Start: 2023-07-17End: 2023-09-26Updated: 2023-11-01

Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

CompletedNCT04312698

Chong Kun Dang PharmaceuticalDyslipidemia Patients With Hypertension

Start: 2019-08-29End: 2021-06-18Updated: 2021-07-28